Endometrial Cancer

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

In the NRG GY018 trial, the addition of pembrolizumab to standard-of-care chemotherapy followed by maintenance pembrolizumab demonstrated a reduction in risk of disease progression or death in patients with advanced or recurrent endometrial cancer.

Early responses were shown with to lenvatinib plus pembrolizumab in the mismatch repair proficient and all-comer populations of patients with advanced endometrial cancer.

The phase 1b SOLAR trial which evaluated olaparib plus selumetinib in patients with RAS-mutated ovarian or endometrial cancer showed there to be a clinical benefit with the combination.

A correlation in total scores were seen between the gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire, according to findings presented at the 2023 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.

Casey M. Cosgrove, MD, discusses biomarker-guided treatment for endometrial cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bhavana Pothuri, MD, MS, discussed with participants their experiences managing adverse events of immunotherapy for advanced endometrial cancer.

David O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.

A regular approval has been granted to dostarlimab for the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.

Early findings from the phase 2 OATH trial show treatment with ONA-XR plus anastrozole elicits a 4-month progression- free survival rate of 77% and overall response rate of 22% in patients with HR-positive metastatic endometrial cancer.

During a Targeted Oncology case-based roundtable event, Robert Coleman, MD, discussed dosing of lenvatinib plus pembrolizumab in patients with endometrial carcinoma.

The phase 3 NRG-GY018 trial of pembrolizumab and standard of care chemotherapy led to a clinically meaningful improvement in progression-free survival vs standard of care alone in endometrial carcinoma regardless of mismatch repair status.

According to a follow-up analysis of the phase 1b/2 study 111/KEYNOTE-146, lenvatinib/pembrolizumab continued to show tumor responses, overall survival, and progression-free survival benefits in endometrial cancer.

Due to its potential to fill a treatment gap in the HER-low and HER-positive endometrial cancer space, DB-1303 now has an FDA fast track designation.

Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.

Insights into the goals of second-line therapy for patients with advanced/recurrent endometrial carcinoma, and best strategies for adverse event management.

Dr Robert Holloway explains what second-line treatment regimen he would have chosen for the patient with metastatic endometrial cancer in the presented case.

Robert Holloway, MD, review safety and efficacy data from a clinical trial investigation of lenvatinib combined with pembrolizumab for the treatment of advanced endometrial cancer.

An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.

Dr Robert Holloway describes the presentation of a typical patient with metastatic endometrial cancer, and whether all patients receive MMR testing.

Robert Holloway, MD, presents the diagnosis and treatment regimen of a 71-year-old woman with mismatch repair-proficient (pMMR) metastatic endometrial cancer.

According to The Cancer Genome Atlas and the ProMisE algorithm, there are 4 molecular subtypes of endometrial cancer, including POLE, dMMR, p53 abnormal, and no specific molecular profile.

Wesley Burkett, MD, discusses the next steps for treating patients with endometrial cancer.

David O’Malley, MD, discusses updated results from the KEYNOTE-158 trial of pembrolizumab in patients with advanced endometrial cancer.

The phase 2 RUBY clinical trial has met its primary end point with dostarlimab-gxly given after chemotherapy achieving progression-free survival improvement in adult patients with primary advanced or recurrent endometrial cancer.

Patients with endometrial cancer were more likely to have cardiovascular disease before and after their cancer diagnosis compared with patients without cancer.

Shannon N. Westin, MD, MPH, discusses the promising results of the ENPAC trial that showed the effectiveness of adding enzalutamide to standard of care chemotherapy for patients with recurrent endometriod cancer.

Wesley Burkett, MD, adiscusses his excitement for the approval of pembrolizumab in combination with lenvatinib for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient.

Closing out her discussion on the management of recurrent metastatic endometrial cancer, Bhavana Pothuri, MD, highlights ongoing clinical trials and novel treatment modalities.